| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2012: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
I examined the prediction factor for the relapse frequency and steroid reactivity in pediatric patients with nephrotic syndrome from the T-cell receptor (TCR) diversity. In evaluation by Complexity Score (CS) obtained from the both analysis of the Vβ repertoire and the CDR3 size spectra typing in CD8+ T-cell, I have predicted that a case whose CS was less than 5.0 points was intractable more. Based on this result, we produced a new protocol the clinical trial using the immunosuppressive agents from the early phase of this illness. We are going to start the new clinical trial in future. In addition, although clonal analysis in which the diversity of TCR structure is lost was also enforced, we ware not able to discover a same clone that suggests a cause of the nephrotic syndrome.
|
